Press Releases

Dr. Lusong Luo of BeiGene was Selected to the 2013 “Beijing Technology” Hundred Talents Program

May 21, 2013 at 8:44 PM EDT

May 2013, Lusong Luo, Ph. D. of Beigene (Beijing) Co. Ltd, was selected to take part in 2013 “Beijing Technology” hundred talents training program. A total of 30 individuals from across multiple technology background were selected for the program. These individuals are from Information Technology, hi-tech equipment manufacturing, energy conservation, urban development and traffic management, agriculture, design, pharmaceutical, medical science, new-age material, alternative energy, and etc, more than 10 key professional fields in Beijing.

As one of the twelve priority talent training programs outlined in <<The capital city plan for medium – and long-term talent development (2010-2020)>>, “Beijing Technology” hundred talents training program is an important measures for Beijing to strengthen and develop talents in high-tech innovative fields. It is the program goal, within the timeline of 2010 to 2020, to train hundreds of talent, who excel in their global specialty field, with excellent management skills, significant technology innovation and contribution, as well as capable to promote and lead business transformation of these new technology to the market place. The training program motto is “Talent, Team Work, Lead”. These talents will become the corner stones of further technology innovation and play a prominent role in the capital city economic and social development.

For more information, please contact:

About BeiGene
BeiGene is a Chinese life sciences biotechnology company based in the Zhongguancun Life Science Park in Beijing that is focused on discovering and developing innovative oncology drugs that encompass novel small molecules and biologics. BeiGene is pursuing this through its own internal discovery laboratories in China and by in-licensing from pharmaceutical partners investigational therapeutics that address unmet medical needs for Chinese and Asian patients with cancer. BeiGene is also creating a robust biomarkers and bioinformatics platform to enable the identification of specific subsets of patient populations who will most likely benefit from the use of specific drugs or treatments.

For more information, please visit